FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2740384497> ?p ?o ?g. }

• W2740384497 endingPage "838" @default.
• W2740384497 startingPage "832" @default.
• W2740384497 abstract "<h3>Objective</h3> Short-term efficacy of induction therapy with intravenous immunoglobulin (Ig) in patients with chronic inflammatory demyelinating polyneuropathy (CIDP) is well established. However, data of previous studies on maintenance therapy were limited up to 24-week treatment period. We aimed to investigate the efficacy and safety of longer-term intravenous Ig therapy for 52 weeks. <h3>Methods</h3> This study was an open-label phase 3 clinical trial conducted in 49 Japanese tertiary centres. 49 patients with CIDP who fulfilled diagnostic criteria were included. After an induction intravenous Ig therapy (0.4 g/kg/day for five consecutive days), maintenance dose intravenous Ig (1.0 g/kg) was given every 3 weeks for up to 52 weeks. The primary outcome measures were the responder rate at week 28 and relapse rate at week 52. The response and relapse were defined with the adjusted Inflammatory Neuropathy Cause and Treatment scale. <h3>Results</h3> At week 28, the responder rate was 77.6% (38/49 patients; 95% CI 63% to 88%), and the 38 responders continued the maintenance therapy. At week 52, 4 of the 38 (10.5%) had a relapse (95% CI 3% to 25%). During 52 weeks, 34 (69.4%) of the 49 enrolled patients had a maintained improvement. Adverse events were reported in 94% of the patients; two patients (66-year-old and 76-year-old men with hypertension or diabetes) developed cerebral infarction (lacunar infarct with good recovery), and the other adverse effects were mild and resolved by the end of the study period. <h3>Conclusions</h3> Maintenance treatment with 1.0 g/kg intravenous Ig every 3 weeks is an efficacious therapy for patients with CIDP, and approximately 70% of them had a sustained remission for 52 weeks. Thrombotic complications should be carefully monitored, particularly in elderly patients with vascular risk factors. <h3>Trial registration number</h3> ClinicalTrials.gov (NCT01824251)." @default.
• W2740384497 created "2017-08-08" @default.
• W2740384497 creator A5009588500 @default.
• W2740384497 creator A5011492264 @default.
• W2740384497 creator A5014489789 @default.
• W2740384497 creator A5015941558 @default.
• W2740384497 creator A5016131935 @default.
• W2740384497 creator A5018262222 @default.
• W2740384497 creator A5036040469 @default.
• W2740384497 creator A5036796689 @default.
• W2740384497 creator A5037584672 @default.
• W2740384497 creator A5045535997 @default.
• W2740384497 creator A5055400330 @default.
• W2740384497 creator A5056856867 @default.
• W2740384497 creator A5059512239 @default.
• W2740384497 creator A5068203165 @default.
• W2740384497 creator A5071195473 @default.
• W2740384497 creator A5072735319 @default.
• W2740384497 creator A5086153164 @default.
• W2740384497 creator A5087343109 @default.
• W2740384497 date "2017-08-02" @default.
• W2740384497 modified "2023-10-06" @default.
• W2740384497 title "Intravenous immunoglobulin for maintenance treatment of chronic inflammatory demyelinating polyneuropathy: a multicentre, open-label, 52-week phase III trial" @default.
• W2740384497 cites W1730276021 @default.
• W2740384497 cites W1965507151 @default.
• W2740384497 cites W1967541365 @default.
• W2740384497 cites W1974551350 @default.
• W2740384497 cites W1997980896 @default.
• W2740384497 cites W1998220061 @default.
• W2740384497 cites W2003146702 @default.
• W2740384497 cites W2022210867 @default.
• W2740384497 cites W2040160619 @default.
• W2740384497 cites W2047134888 @default.
• W2740384497 cites W2056518988 @default.
• W2740384497 cites W2093997579 @default.
• W2740384497 cites W2094965101 @default.
• W2740384497 cites W2110199093 @default.
• W2740384497 cites W2127180052 @default.
• W2740384497 cites W2127776176 @default.
• W2740384497 cites W2131889474 @default.
• W2740384497 cites W2170208876 @default.
• W2740384497 cites W2338837901 @default.
• W2740384497 cites W2415929792 @default.
• W2740384497 cites W2597670594 @default.
• W2740384497 cites W2965965202 @default.
• W2740384497 doi "https://doi.org/10.1136/jnnp-2017-316427" @default.
• W2740384497 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/5629934" @default.
• W2740384497 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/28768822" @default.
• W2740384497 hasPublicationYear "2017" @default.
• W2740384497 type Work @default.
• W2740384497 sameAs 2740384497 @default.
• W2740384497 citedByCount "37" @default.
• W2740384497 countsByYear W27403844972018 @default.
• W2740384497 countsByYear W27403844972019 @default.
• W2740384497 countsByYear W27403844972020 @default.
• W2740384497 countsByYear W27403844972021 @default.
• W2740384497 countsByYear W27403844972022 @default.
• W2740384497 countsByYear W27403844972023 @default.
• W2740384497 crossrefType "journal-article" @default.
• W2740384497 hasAuthorship W2740384497A5009588500 @default.
• W2740384497 hasAuthorship W2740384497A5011492264 @default.
• W2740384497 hasAuthorship W2740384497A5014489789 @default.
• W2740384497 hasAuthorship W2740384497A5015941558 @default.
• W2740384497 hasAuthorship W2740384497A5016131935 @default.
• W2740384497 hasAuthorship W2740384497A5018262222 @default.
• W2740384497 hasAuthorship W2740384497A5036040469 @default.
• W2740384497 hasAuthorship W2740384497A5036796689 @default.
• W2740384497 hasAuthorship W2740384497A5037584672 @default.
• W2740384497 hasAuthorship W2740384497A5045535997 @default.
• W2740384497 hasAuthorship W2740384497A5055400330 @default.
• W2740384497 hasAuthorship W2740384497A5056856867 @default.
• W2740384497 hasAuthorship W2740384497A5059512239 @default.
• W2740384497 hasAuthorship W2740384497A5068203165 @default.
• W2740384497 hasAuthorship W2740384497A5071195473 @default.
• W2740384497 hasAuthorship W2740384497A5072735319 @default.
• W2740384497 hasAuthorship W2740384497A5086153164 @default.
• W2740384497 hasAuthorship W2740384497A5087343109 @default.
• W2740384497 hasBestOaLocation W27403844971 @default.
• W2740384497 hasConcept C126322002 @default.
• W2740384497 hasConcept C141071460 @default.
• W2740384497 hasConcept C159654299 @default.
• W2740384497 hasConcept C197934379 @default.
• W2740384497 hasConcept C203014093 @default.
• W2740384497 hasConcept C2775892965 @default.
• W2740384497 hasConcept C2776694085 @default.
• W2740384497 hasConcept C2778283404 @default.
• W2740384497 hasConcept C2779867792 @default.
• W2740384497 hasConcept C2909916134 @default.
• W2740384497 hasConcept C535046627 @default.
• W2740384497 hasConcept C71924100 @default.
• W2740384497 hasConcept C90924648 @default.
• W2740384497 hasConceptScore W2740384497C126322002 @default.
• W2740384497 hasConceptScore W2740384497C141071460 @default.
• W2740384497 hasConceptScore W2740384497C159654299 @default.
• W2740384497 hasConceptScore W2740384497C197934379 @default.
• W2740384497 hasConceptScore W2740384497C203014093 @default.
• W2740384497 hasConceptScore W2740384497C2775892965 @default.
• W2740384497 hasConceptScore W2740384497C2776694085 @default.

• next